RxDoctor Payments Data

Michele Tjaden, NP

Family · Hockessin, DENPI 1730626755

Payments from drug & device makers

$606in general payments, 2019–2025

Across 28 payments — averaging $21.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$223
  • Astellas Pharma US Inc$100
  • Lilly USA, LLC$72
  • Novo Nordisk$60
  • Abbott$46
  • Pfizer$39
  • plus $66 from 3 others

What the payments were for

  • Food & beverage$50683%
  • Education$10017%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$606 in reported general payments places this provider in the 55th percentile of 523 family providers in Delaware.

See all family providers in Delaware

Medicare billing

Part B allowed, 2024
$2,942
Medicare patients
43
Services billed
47

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin38$49,145
OzempicSemaglutide26$48,766
MounjaroTirzepatide19$26,046
RybelsusSemaglutide12$25,676
EliquisApixaban19$24,836
JanuviaSitagliptin Phosphate11$16,103
LinzessLinaclotide16$15,119
Atorvastatin Calcium370$5,222
Ezetimibe53$2,504
Rosuvastatin Calcium95$2,409
Albuterol Sulfate HfaAlbuterol Sulfate58$2,314
Bupropion XlBupropion Hcl50$2,294
Omeprazole163$2,214
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$2,122
Azelastine Hcl66$2,086

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$60$74,44238 claims
Boehringer IngelheimJardiance$37$49,14538 claims
Lilly USA, LLCMounjaro$72$26,04619 claims
PfizerEliquis$39$24,83619 claims
AbbVieLinzess, Synthroid$223$17,12058 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 523 family providers in Delaware.

Other family in Hockessin

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →